Trial Profile
Phase I/Ib Study of Combined Pembrolizumab Plus Guadecitabine and Mocetinostat for Patients With Advanced NSCLC (DOSE SELECTION)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Guadecitabine (Primary) ; Mocetinostat (Primary) ; Pembrolizumab (Primary)
- Indications Lung cancer; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms DOSE SELECTION
- 01 Aug 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 01 Aug 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.
- 01 Aug 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.